Anhui Double-Crane’s Metronidazole and Sodium Chloride Injection Passed the Consistency Evaluation of Quality and Efficacy of Generic Drugs

Anhui Double-Crane’s Metronidazole and Sodium Chloride Injection Passed the...

CR Double-Crane announced on January 22nd that its wholly-owned subsidiary Double-Crane Pharmaceutical (Anhui) received the Approv...

Detailed>>

Detailed +

2022.01

2022.01.22

Anhui Double-Crane’s Metronidazole and Sodium Chloride Injection Passed the Consistency Evaluation of Quality and Efficacy of Generic Drugs

Anhui Double-Crane’s Metronidazole and Sodium Chloride Injection Passed the...

CR Double-Crane announced on January 22nd that its wholly-owned subsidiary Double-Crane Pharmaceutical (Anhui) received the Approval Document from the National Medical Products Administration (“NMPA”) on Drug Supplementary Application for Metronidazole and Sodium Chloride Injection (100ml) on January 5th (Document No.: 2022B00015), which marked that the drug had passed the consistency evaluation of quality and efficacy of generic drugs.

CR Double-Crane announced on January 22nd that its wholly-owned subsidiary Double-Crane Pharmaceutical (Anhui) received the Approv...

2021.11

2021.11.12

Novel Cancer Drug of CR Double-Crane Released and the Signing Ceremony between Haikou National Hi-tech Zone and CR Double-Crane Convened

Novel Cancer Drug of CR Double-Crane Released and the Signing Ceremony betw...

At 9: 00 on November 11, 2021, a novel cancer drug was released by CR Double-Crane, and the signing ceremony between the company and Haikou National Hi-tech Industrial Development Zone was held in the office building of Haikou Municipal Government.

At 9: 00 on November 11, 2021, a novel cancer drug was released by CR Double-Crane, and the signing ceremony between the company a...

2021.10

2021.10.09

NIP Pharm’s Innovative Drug NIP142 Approved for Clinical Trials for NSCLC

Recently, National Institute of Pharmaceutical R&D Co., Ltd. (NIP Pharm), a subsidiary of CR Pharmaceutical Group, received the Notice of Drug Clinical Trial Approval from the National Medical Products Administration (NMPA), approving its clinical trials of the NIP142 capsules for non-small cell lung cancer (NSCLC).

Recently, National Institute of Pharmaceutical R&D Co., Ltd. (NIP Pharm), a subsidiary of CR Pharmaceutical Group, received the No...

2021.10

2021.10.08

A Delegation Led by Zhang Boli Visiting CR Sanjiu

2021.09

2021.09.17

Remaining Committed to Charity - The CR Healthy Village Program Keeping up the Good Work

Remaining Committed to Charity - The CR Healthy Village Program Keeping up ...

2021.08

2021.08.04

CR Double-Crane’s Sodium Valproate Tablets Fluconazole and Sodium Chloride Injection Passing Consistency Evaluation of Generic Drugs

CR Double-Crane’s Sodium Valproate Tablets Fluconazole and Sodium Chloride ...

CR Double-Crane’s Sodium Valproate Tablets Fluconazole and Sodium Chloride Injection Passing Consistency Evaluation of Generic Drugs

CR Double-Crane’s Sodium Valproate Tablets Fluconazole and Sodium Chloride Injection Passing Consistency Evaluation of Generic Dru...

2021.07

2021.07.21

CR Double-Crane and NOVITA signed an exclusive license agreement on the development, production and commercialization of NP-G2-044 Fascin inhibitor in Greater China.

CR Double-Crane and NOVITA signed an exclusive license agreement on the dev...

2021.07

2021.07.20

CR Pharmaceutical proposed to acquire 10.0% stake in Immunotech Biopharm

2021.07

2021.07.12

CR Biopharmaceutical and Biocytogen reach a comprehensive strategic cooperation for the development of multiple target antibody drugs

CR Biopharmaceutical and Biocytogen reach a comprehensive strategic coopera...

On July 12, China Resources Biopharmaceutical Co., Ltd. (hereafter referred to as CR Biopharmaceutical) and Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (hereafter referred to as Biocytogen) reached comprehensive strategic cooperation.

On July 12, China Resources Biopharmaceutical Co., Ltd. (hereafter referred to as CR Biopharmaceutical) and Biocytogen Pharmaceuti...

2021.07

2021.07.07

CR Pharmaceutical’s proposed acquisition of a controlling stake in Boya Bio-pharmaceutical[2019 report] was approved by the SASAC

CR Pharmaceutical’s proposed acquisition of a controlling stake in Boya Bio...

CR Pharmaceutical’s proposed acquisition of a controlling stake in Boya Bio-pharmaceutical？was approved by the SASAC.

1 2 3 ... 5 Next